Kenny and Bissell (2007) showed that inhibition of TACE protease activity blocked EGFR signalling, resulting in a reversion of the malignant phenotype of T4-2 breast cancer cells. Inhibition of TACE using selective inhibitors also decreased cell proliferation in an in vitro model of colorectal cancer (Merchant et al, 2008). The gene discussed is ADAM17; the disease is breast cancer.